Diana Ernst

RPh

Most Recent Articles by Diana Ernst

Orilissa Approved for Moderate to Severe Pain Associated With Endometriosis

Orilissa Approved for Moderate to Severe Pain Associated With Endometriosis

By

The approval was based on data from 2 multinational double-blind, placebo-controlled Phase 3 trials involving 1686 premenopausal women with moderate to severe pain associated with endometriosis.

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

By

The 16-week, double-blind, placebo-controlled, multicenter, parallel-group study included 698 patients who were randomized to 3 treatment groups: 2 doses of tanezumab 2.5mg; 1 dose of tanezumab 2.5mg followed by tanezumab 5mg, or 2 doses of placebo; each injection was administered once every 8 weeks.

Are Anticonvulsants Effective for Low Back Pain?

Are Anticonvulsants Effective for Low Back Pain?

By

For this review, the authors searched 5 large databases for studies that compared the use of anticonvulsants (i.e., topiramate, gabapentin, pregabalin) in adult patients with LBP, sciatica, or neurogenic claudication with placebo.

First Generic Versions of Suboxone Get FDA Approval for Opioid Dependence

First Generic Versions of Suboxone Get FDA Approval for Opioid Dependence

By

The treatment combines buprenorphine, a partial-opioid agonist, with naloxone, an opioid antagonist.

Olinciguat Granted Orphan Drug Status for Sickle Cell Disease

Olinciguat Granted Orphan Drug Status for Sickle Cell Disease

By

Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.

More Articles by Diana Ernst

Sign Up for Free e-Newsletters